Nemaura Medical Announces Presentation on its Licensed Why WAIT Program During the American Diabetes Association 81st Annual ...
June 30 2021 - 9:15AM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”),
a medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces a presentation referring to its licensed Why WAIT®
program at the American Diabetes Association’s 81st Annual
Scientific Sessions.
The Why WAIT program is an award-winning 12-week
program to help patients manage their weight and diabetes
conditions. The Why WAIT® program was developed by the Joslin
Diabetes Center in Boston, MA and demonstrated long-term success.
Healthimation Inc. currently has the exclusive license to develop a
mobile version of Why WAIT® program. Nemaura Medical Inc. licensed
the Why WAIT mobile application from Healthimation to be included
in its BEAT® diabetes program. The Why WAIT® mobile application and
telehealth were used in the virtual Why WAIT® program, which was
compared in the study to the in-person Why WAIT®.
The study presented on June 28th showed no
difference in clinical outcomes between virtual Why WAIT® and
in-person Why WAIT® programs, where both resulted in equal weight
loss of ~7% and similar reduction in A1C of ~1%.
Highlights from the presentation included:
-
The potentiality for group intervention through telemedicine or mobile health
applications as a result of recent advances in digital health
-
Advantages of utilizing digital health applications for
participants to maintain accurate records of their dietary,
exercise and behavioural interventions, as well as inclusion of
coaching modules that allow tracking of personal progress
-
Virtual multidisciplinary intensive lifestyle intervention programs
using telemedicine and m-health are as effective as costly,
in-person physical programming to improve body weight, A1C, blood
pressure, lipid profiles and in reducing the number of
hyperglycemic medications
-
The virtual Why WAIT® program can be scalable to overweight and
obese people with diabetes, regardless of their locations and may
be as successful as in-person programs
“Our BEAT® diabetes program, which combines our
non-invasive glucose monitors with mobile Why WAIT® program from
Healthimation, is an important advance in our understanding of
effective diabetes management and prevention, and this presentation
at the American Diabetes Association’s Scientific Sessions outlines
the keys to their success,” said Nemaura CEO Dr. Faz Chowdhury.
“This validation is an important step towards validating our
combined program, as we embark on a scalable growth plan. We look
forward to continuing to provide updates on our progress.”
Nemaura has combined the mobile Why WAIT® progam
with the company’s proBEAT™ non-invasive patch CGM (continuous
glucose monitor) for enhanced behavioral change experience, to form
its proprietary BEATdiabetes program. Developed at a major diabetes
center in the U.S. over more than 15 years, the digital program
curriculum implements the most advanced approach to nutrition,
exercise, and behavioral change and has been clinically tested and
has demonstrated many benefits to a patient’s overall health,
including weight reduction, significant improvements in A1C, lipid
profile, and blood pressure, and a reduction in medications
taken.
About Nemaura
Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program.
The Company believes that it sits at the
intersection of the global Type 2 diabetes market that is expected
to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic
market, and the wearable health-tech sector for weight loss and
wellness applications that is estimated to reach $60 billion by
2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the US, risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate their decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
Contact:Jules AbrahamCORE
IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024